APA (7th ed.) Citation

Hyland, E., Mant, T., Vlachos, P., Attkins, N., Ullmann, M., Roy, S., & Wagner, V. (2016). Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects. British journal of clinical pharmacology, 82(4), 983-993. https://doi.org/10.1111/bcp.13039

Chicago Style (17th ed.) Citation

Hyland, Elizabeth, Tim Mant, Pantelis Vlachos, Neil Attkins, Martin Ullmann, Sanjeev Roy, and Volker Wagner. "Comparison of the Pharmacokinetics, Safety, and Immunogenicity of MSB11022, a Biosimilar of Adalimumab, with Humira® in Healthy Subjects." British Journal of Clinical Pharmacology 82, no. 4 (2016): 983-993. https://doi.org/10.1111/bcp.13039.

MLA (9th ed.) Citation

Hyland, Elizabeth, et al. "Comparison of the Pharmacokinetics, Safety, and Immunogenicity of MSB11022, a Biosimilar of Adalimumab, with Humira® in Healthy Subjects." British Journal of Clinical Pharmacology, vol. 82, no. 4, 2016, pp. 983-993, https://doi.org/10.1111/bcp.13039.